Let’s build something together
At Polpharma Biologics, we believe in the power of partnerships to unlock new possibilities in biosimilars. We collaborate with visionary companies — from global pharma leaders to innovative suppliers — to accelerate development, scale smarter, and expand access to life-changing biologics around the world.
Our approach to partnering
At Polpharma Biologics Switzerland AG , collaboration is in our DNA. As a fast-moving team building the next generation of biosimilars, we value transparency, agility, and shared ambition. Whether it’s bringing a molecule to market or streamlining supply chains, we believe in partnerships that create real-world impact.
We’re particularly interested in partners who want to co-create go-to-market strategies, contribute to tech transfer, or support our clinical ambitions across the US, Europe, and emerging markets.
Ready to join us on this journey?
Meet our commercial partners
We’re proud to collaborate with a growing network of leading partners who help us push boundaries, accelerate timelines, and make a difference in patients’ lives.
We have entered into a joint venture company, Bioeq, with Santo Holding AG (Strüngmann Group) for the development of the biosimilar Ranibizumab.
The biosimilar was originally licensed from Formycon AG and subsequently developed by Bioeq AG
We have entered a global commercialization agreement with Sandoz AG for the commercialization of our natalizumab biosimilar
Under the agreement, we are responsible for the development, manufacturing and supply of the collaboration biosimilar. Sandoz have global commercialisation rights.
We have entered into an out-licensing agreement with MS Pharma for the commercialization of biosimilars Ocrelizumab, Vedolizumab, and Guselkumab in the Middle East and North Africa
MS Pharma will lead commercialization activities across the MENA region, while we continue to oversee development and supply to ensure patients gain access to high-quality, affordable biologics.
We have entered into an out-licensing agreement with Fresenius Kabi for the commercialization of biosimilar Vedolizumab
Under the agreement, Fresenius Kabi holds commercialization rights for biosimilar Vedolizumab in all territories except the Middle East and North Africa.
We remain responsible for the development, manufacturing, and supply of the biosimilar.
Meet our supplier partners
Every successful biosimilar is powered by a network of exceptional suppliers. We collaborate with best-in-class partners who deliver reliable, scalable, and compliant solutions — from advanced analytics and raw materials to full-scale commercial manufacturing.
We have entered a global commercialization agreement with Sandoz AG for the commercialization of our natalizumab biosimilar
Under the agreement, we are responsible for the development, manufacturing and supply of the collaboration biosimilar. Sandoz have global commercialisation rights.
Our areas of interest
We focus on biosimilars with the potential to lead—whether first to market or designed for niche, high-impact needs. Our programs are grounded in data, feasibility, and global demand.